These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18197163)

  • 1. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. New drugs--hope and a degree of caution.
    TreatmentUpdate; 2007; 19(6):9-10. PubMed ID: 18041153
    [No Abstract]   [Full Text] [Related]  

  • 3. Pivotal moments in HIV treatment: the 14th CROI.
    Laurence J
    AIDS Read; 2007 May; 17(5):239-40. PubMed ID: 17532657
    [No Abstract]   [Full Text] [Related]  

  • 4. [New antiretroviral drug classes in HIV therapy].
    Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
    MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in HIV therapeutics: the 14th CROI.
    Boyle BA; Elion R; Cohen CJ; Moyle GJ; Sax P; Frank I
    AIDS Read; 2007 May; 17(5):268-70, 272-4, 283-6. PubMed ID: 17532664
    [No Abstract]   [Full Text] [Related]  

  • 7. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.
    Stephenson J
    JAMA; 2007 Apr; 297(14):1535-6. PubMed ID: 17426263
    [No Abstract]   [Full Text] [Related]  

  • 8. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
    Horster S; Goebel FD
    Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir, a new HIV integrase inhibitor.
    Gandhi RT
    AIDS Clin Care; 2007 Dec; 19(12):105. PubMed ID: 18399003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 14. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV integrase inhibitors--out of the pipeline and into the clinic.
    Havlir DV
    N Engl J Med; 2008 Jul; 359(4):416-8. PubMed ID: 18650518
    [No Abstract]   [Full Text] [Related]  

  • 16. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
    Vandekerckhove L; Verhofstede C; Vogelaers D
    J Antimicrob Chemother; 2008 Jun; 61(6):1187-90. PubMed ID: 18400807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 18. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV agents. Maraviroc approved in Canada.
    TreatmentUpdate; 2007; 19(6):1-3. PubMed ID: 18041146
    [No Abstract]   [Full Text] [Related]  

  • 20. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.